A retrospective analysis on 42 AML patients receiving either decitabine or 5-AZA suggested an improvement in overall HMA-treatment response for patients with IDH mutations with 71.4% versus 22.9% for IDH wt patients [73]. Here, IDH2 is linked to acute myeloid leukemia.